Sarepta Plans FDA Run for Duchenne Exon Skippers Despite Confirmatory Trial Failure

Why It Matters

Full approval would lock in revenue and preserve patient access, while also signaling FDA openness to real‑world data for rare‑disease drugs.

Key Takeaways

• FDA reviewing supplemental data for Amondys 45, Vyondys 53.
• Confirmatory trial missed primary motor function endpoint.
• Real‑world data suggest lung and ventilation benefits.
• Potential full approval could prevent market withdrawal.
• Sarepta faces leadership exit and Elevidys safety issues.

Pulse Analysis

Sarepta Therapeutics' two exon‑skipping drugs, Amondys 45 and Vyondys 53, have been cornerstones of its Duchenne muscular dystrophy (DMD) portfolio since receiving accelerated approval in 2021 and 2019 respectively. The accelerated pathway required a post‑marketing confirmatory study, the ESSENCE trial, to demonstrate a meaningful improvement in motor function. The study, however, failed to meet its primary endpoint, showing no statistically significant increase in step count. This shortfall placed the therapies in a regulatory limbo, prompting the company to seek an alternative route to retain market access.

To compensate for the trial outcome, Sarepta compiled real‑world evidence from more than 1,800 patients spanning infants to adults. The data indicate a 7.5‑year delay in nighttime ventilation for Vyondys 53 and a measurable slowdown in lung‑function decline for Amondys 45, along with possible extensions in ambulation and survival. The FDA has agreed to accept this supplemental package, reflecting a broader shift toward integrating real‑world data when traditional endpoints are hard to capture in ultra‑rare diseases. If accepted, the agency could set a precedent for future accelerated‑approval conversions.

The stakes are high for Sarepta. Converting the accelerated approvals to traditional status would secure a steady revenue stream and protect patients from abrupt drug withdrawal. The filing coincides with CEO Doug Ingram’s planned exit and heightened scrutiny after several Elevidys‑related deaths, which have already dented sales. A successful conversion could restore investor confidence and give the company breathing room to address safety concerns and advance its gene‑therapy pipeline. Conversely, a denial would likely force a market exit, intensifying competition from emerging DMD therapies and reshaping the rare‑disease landscape.